Soluble perlecan domain i enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells

BMC Biochemistry

Volumn 11, Issue 1, 2010, Pages

  Muthusamy, Arivalagan ^a   Cooper, Carlton R ^b   Gomes Jr , Ronald R ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; HEPARAN SULFATE; HEPARIN LYASE; MONOCLONAL ANTIBODY; N ACETYLGALACTOSAMINE 4 SULFATASE; NEUROPILIN 1; PERLECAN; PROTEIN KINASE B; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN PERLECAN DOMAIN I; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; PROTEOHEPARAN SULFATE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BONE MARROW CELL; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SOLUBILITY;

BONE MARROW CELLS; ENDOTHELIAL CELLS; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78049344435     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-11-43     Document Type: Article

References (48)

1. Basement membrane proteoglycans: from cellar to ceiling. RV Iozzo, Nat Rev Mol Cell Biol 2005 6 8 646 656 10.1038/nrm1702 16064139
2. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. DM Noonan A Fulle P Valente S Cai E Horigan M Sasaki Y Yamada JR Hassell, J Biol Chem 1991 266 34 22939 22947 1744087
3. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. AD Murdoch GR Dodge I Cohen RS Tuan RV Iozzo, J Biol Chem 1992 267 12 8544 8557 1569102
4. Novel interactions of perlecan: unraveling perlecan's role in angiogenesis. G Bix RV Iozzo, Microsc Res Tech 2008 71 5 339 348 10.1002/jemt.20562 18300285
5. HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses. S D'Souza W Yang D Marchetti C Muir MC Farach-Carson DD Carson, J Cell Biochem 2008 105 5 1183 1193 10.1002/jcb.21899 18980226
6. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. JJ Zoeller JM Whitelock RV Iozzo, Matrix Biol 2009 28 5 284 291 10.1016/j.matbio.2009.04.010 19422911
7. Vascular endothelial growth factor (VEGF) and its receptors. G Neufeld T Cohen S Gengrinovitch Z Poltorak, FASEB J 1999 13 1 9 22 9872925
8. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. C de Vries JA Escobedo H Ueno K Houck N Ferrara LT Williams, Science 1992 255 5047 989 991 10.1126/science.1312256 1312256
9. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. BI Terman M Dougher-Vermazen ME Carrion D Dimitrov DC Armellino D Gospodarowicz P Bohlen, Biochem Biophys Res Commun 1992 187 3 1579 1586 10.1016/0006-291X(92)90483-2 1417831
10. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. B Millauer S Wizigmann-Voos H Schnurch R Martinez NP Moller W Risau A Ullrich, Cell 1993 72 6 835 846 10.1016/0092-8674(93)90573-9 7681362
11. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Waltenberger L Claesson-Welsh A Siegbahn M Shibuya CH Heldin, J Biol Chem 1994 269 43 26988 26995 7929439
12. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. H Gille J Kowalski B Li J LeCouter B Moffat TF Zioncheck N Pelletier N Ferrara, J Biol Chem 2001 276 5 3222 3230 10.1074/jbc.M002016200 11058584
13. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. S Soker S Takashima HQ Miao G Neufeld M Klagsbrun, Cell 1998 92 6 735 745 10.1016/S0092-8674(00)81402-6 9529250
14. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. H Gitay-Goren S Soker I Vlodavsky G Neufeld, J Biol Chem 1992 267 9 6093 6098 1556117
15. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. R Mamluk Z Gechtman ME Kutcher N Gasiunas J Gallagher M Klagsbrun, J Biol Chem 2002 277 27 24818 24825 10.1074/jbc.M200730200 11986311
16. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. S Gengrinovitch B Berman G David L Witte G Neufeld D Ron, J Biol Chem 1999 274 16 10816 10822 10.1074/jbc.274.16.10816 10196157
17. Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. WD Yang RR Gomes Jr M Alicknavitch MC Farach-Carson DD Carson, Tissue Eng 2005 11 1-2 76 89 10.1089/ten.2005.11.76 15738663
18. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. SM Smith LA West P Govindraj X Zhang DM Ornitz JR Hassell, Matrix Biol 2007 26 3 175 184 10.1016/j.matbio.2006.10.012 17169545
19. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. K Holmes OL Roberts AM Thomas MJ Cross, Cell Signal 2007 19 10 2003 2012 10.1016/j.cellsig.2007.05.013 17658244
20. Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. W Yang RR Gomes AJ Brown AR Burdett M Alicknavitch MC Farach-Carson DD Carson, Tissue Eng 2006 12 7 2009 2024 10.1089/ten.2006.12.2009 16889529
21. Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. M Costell K Mann Y Yamada R Timpl, Eur J Biochem 1997 243 1-2 115 121 10.1111/j.1432-1033.1997.t01-1-00115.x 9030729
22. Diverse cell signaling events modulated by perlecan. JM Whitelock J Melrose RV Iozzo, Biochemistry 2008 47 43 11174 11183 10.1021/bi8013938 18826258
23. Isolation and identification of the major heparan sulfate proteoglycans in the developing bovine rib growth plate. P Govindraj L West TJ Koob P Neame K Doege JR Hassell, J Biol Chem 2002 277 22 19461 19469 10.1074/jbc.M200786200 11909863
24. Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity. P Tapanadechopone S Tumova X Jiang JR Couchman, Biochem J 2001 355 Pt 2 517 527 10.1042/0264-6021:3550517 11284741
25. Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors. SMC Knox S Stringer J Melrose J Whitelock, J Biol Chem 2002 277 17 14657 14665 11847221
26. The structure, location, and function of perlecan, a prominent pericellular proteoglycan of fetal, postnatal, and mature hyaline cartilages. J Melrose P Roughley S Knox S Smith M Lord J Whitelock, J Biol Chem 2006 281 48 36905 36914 10.1074/jbc.M608462200 16984910
27. Perlecan from human epithelial cells is a hybrid heparan/chondroitin/ keratan sulfate proteoglycan. S Knox AJ Fosang K Last J Melrose J Whitelock, FEBS Lett 2005 579 22 5019 5023 10.1016/j.febslet.2005.07.090 16129435
28. Biosynthesis of heparan sulfate proteoglycan by human colon carcinoma cells and its localization at the cell surface. RV Iozzo, J Cell Biol 1984 99 2 403 417 10.1083/jcb.99.2.403 6235235
29. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. B Sharma M Handler I Eichstetter JM Whitelock MA Nugent RV Iozzo, J Clin Invest 1998 102 8 1599 1608 10.1172/JCI3793 9788974
30. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. D Aviezer D Hecht M Safran M Eisinger G David A Yayon, Cell 1994 79 6 1005 1013 10.1016/0092- 8674(94)90031-0 7528102
31. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. CJ Robinson B Mulloy JT Gallagher SE Stringer, J Biol Chem 2006 281 3 1731 1740 10.1074/jbc.M510760200 16258170
32. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. S Ashikari-Hada H Habuchi Y Kariya K Kimata, J Biol Chem 2005 280 36 31508 31515 10.1074/jbc.M414581200 16027124
33. Structural features in heparin that interact with VEGF165 and modulate its biological activity. K Ono H Hattori S Takeshita A Kurita M Ishihara, Glycobiology 1999 9 7 705 711 10.1093/glycob/9.7.705 10362840
34. Structure of low density heparan sulfate proteoglycan isolated from a mouse tumor basement membrane. M Paulsson PD Yurchenco GC Ruben J Engel R Timpl, J Mol Biol 1987 197 2 297 313 10.1016/0022-2836(87)90125-2 2960821
35. Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. R Kokenyesi JE Silbert, Biochem Biophys Res Commun 1995 211 1 262 267 10.1006/bbrc.1995.1805 7779094
36. Similarity of Recombinant Human Perlecan Domain 1 by Alternative Expression Systems. AL Ellis W Pan G Yang K Jones C Chuang JM Whitelock AA Decarlo, BMC Biotechnol 10 1 66 10.1186/1472-6750-10-66 20828410
37. Regulation of vascular endothelial growth factor binding and activity by extracellular pH. AL Goerges MA Nugent, J Biol Chem 2003 278 21 19518 19525 10.1074/jbc.M211208200 12637571
38. Perlecan - a multifunctional extracellular proteoglycan scaffold. MC Farach-Carson DD Carson, Glycobiology 2007 17 9 897 905 10.1093/glycob/cwm043 17442708
39. VEGF receptor signalling-in control of vascular function. AK Olsson A Dimberg J Kreuger L Claesson-Welsh, Nat Rev Mol Cell Biol 2006 7 5 359 371 10.1038/nrm1911 16633338
40. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. AM Dougher H Wasserstrom L Torley L Shridaran P Westdock RE Hileman JR Fromm R Anderberg S Lyman RJ Linhardt,, et al. Growth Factors 1997 14 4 257 268 10.3109/08977199709021524 9386990
41. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. S Soker H Fidder G Neufeld M Klagsbrun, J Biol Chem 1996 271 10 5761 5767 10.1074/jbc.271.10.5761 8621443
42. The MUC1 SEA module is a self-cleaving domain. F Levitin O Stern M Weiss C Gil-Henn R Ziv Z Prokocimer NI Smorodinsky DB Rubinstein DH Wreschner, J Biol Chem 2005 280 39 33374 33386 10.1074/jbc.M506047200 15987679
43. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. JM Whitelock AD Murdoch RV Iozzo PA Underwood, J Biol Chem 1996 271 17 10079 10086 10.1074/jbc.271.17.10079 8626565
44. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. MP d'Ortho H Will S Atkinson G Butler A Messent J Gavrilovic B Smith R Timpl L Zardi G Murphy, Eur J Biochem 1997 250 3 751 757 10.1111/j.1432-1033.1997.00751.x 9461298
45. Isolation, characterization, and biologic features of bone marrow endothelial cells. G Almeida-Porada JL Ascensao, J Lab Clin Med 1996 128 4 399 407 10.1016/S0022-2143(96)80012-6 8833889
46. Structural characterization of the bovine tracheal chondroitin sulfate chains and binding of Plasmodium falciparum-infected erythrocytes. A Muthusamy RN Achur M Valiyaveettil SV Madhunapantula I Kakizaki VP Bhavanandan CD Gowda, Glycobiology 2004 14 7 635 645 10.1093/glycob/cwh077 15044390 (Pubitemid 38923645)
47. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases. Y Liu IM Sainz Y Wu R Pixley RG Espinola S Hassan MM Khan RW Colman, Exp Cell Res 2008 314 4 774 788 10.1016/j.yexcr.2007. 10.008 18062965
48. Chondroitin sulfate proteoglycans of bovine cornea: structural characterization and assessment for the adherence of Plasmodium falciparum-infected erythrocytes. RN Achur A Muthusamy SV Madhunapantula VP Bhavanandan C Seudieu D Channe Gowda, Biochim Biophys Acta 2004 1701 1-2 109 119 15450180 (Pubitemid 39140790)